Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Chandra Bhagat Pharma Ltd (CBPL) is currently trading at 44.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Chandra Bhagat Pharma Limited focuses on marketing critical care and pharmaceutical products. It initially began as a private company in 2003, later becoming public in 2019. The company markets a diverse range of pharmaceutical formulations across major therapeutic categories, such as oncology, cardiology, and antibiotics. It has expanded its reach to both the domestic and international markets by obtaining necessary FDA approvals for its contract manufacturing. Mr. Hemant Bhagat, originally leading the company, has maintained focus on life-saving medicines, further expanding its portfolio through strategic marketing. Chandra Bhagat Pharma works with active pharmaceutical ingredients, promoting their use within India, while upholding a robust marketing infrastructure.
Over the past 52 weeks, Chandra Bhagat Pharma Ltd has traded between a low of ₹29.70 and a high of ₹52.71. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Chandra Bhagat Pharma Ltd has a market capitalization of approximately 35.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Chandra Bhagat Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.63 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 35.46 Cr, Chandra Bhagat Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Chandra Bhagat Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Chandra Bhagat Pharma Ltd is 11.63. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company plans to raise ₹29.04 crore through a preferential issue of 66,00,000 convertible warrants.
Chandra Bhagat Pharma Limited focuses on marketing critical care and pharmaceutical products. It initially began as a private company in 2003, later becoming public in 2019.
The company markets a diverse range of pharmaceutical formulations across major therapeutic categories, such as oncology, cardiology, and antibiotics.
It has expanded its reach to both the domestic and international markets by obtaining necessary FDA approvals for its contract manufacturing.
Mr. Hemant Bhagat, originally leading the company, has maintained focus on life-saving medicines, further expanding its portfolio through strategic marketing.
Chandra Bhagat Pharma works with active pharmaceutical ingredients, promoting their use within India, while upholding a robust marketing infrastructure.
Pharmaceuticals & Biotechnology
Pharmaceuticals
35 Cr
Low Risk
11.6
37.7
0.2
1.1
52.71
29.70
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
2
Neutral
7
Bullish
5
Bearish
13
Neutral
15
Bullish
18
Bearish
11
Neutral
8
Bullish
13
Bearish
2
Neutral
7
Bullish
5
Bearish
2
Neutral
7
Bullish
5
Bearish
11
Neutral
8
Bullish
13
Bearish
11
Neutral
8
Bullish
13
Bearish
11
Neutral
8
Bullish
13
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
45.83 | 37 Cr | 284.46 | 2.10 | 0.00 | 23.13 | 15.39 | 0.18 | ||
37.94 | 37 Cr | 23.53 | 1.10 | 0.00 | 3.69 | 5.32 | 2.80 | ||
5.89 | 36 Cr | -3.04 | 0.98 | 0.00 | -33.10 | -32.42 | -21.35 | ||
44.65 | 35 Cr | 11.63 | 1.07 | 0.00 | 9.20 | 12.30 | 3.24 | ||
14.05 | 35 Cr | -1.51 | 4.11 | 0.00 | -117.84 | -25.84 | -37.84 | ||
31.20 | 34 Cr | -18.92 | 0.30 | 0.00 | -2.72 | -2.70 | -1.54 | ||
| Median: 6 Co. | — | 34.57 | 36 Cr | 5.06 | 1.08 | 0.00 | 0.49 | 1.31 | -0.68 |
